David A. Siegel Neu Base Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $20,787 - $48,925	-25,350 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.26 - $2.95 $18,572 - $43,483	-14,740 Reduced 36.77%	25,350 $48,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $360,700 - $579,895	-138,731 Reduced 77.58%	40,090 $113,000
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $82,956 - $120,756	-25,369 Reduced 12.42%	178,821 $646,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $600,974 - $952,732	129,800 Added 174.49%	204,190 $978,000

Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $514,778 - $919,460	74,390 New	74,390 $550,000
Q3 2020 Nov 16, 2020	SELL	$7.25 - $9.71 $177,951 - $238,331	-24,545 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $164,206 - $282,512	24,545 New	24,545 $216,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.